XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents (Note 7) $ 3,223.6 $ 2,818.6
Short-term investments (Note 7) 140.4 109.1
Accounts receivable, net of allowances of $14.4 (2024) and $14.8 (2023) 11,027.9 9,090.5
Other receivables 2,051.1 2,245.7
Inventories (Note 6) 6,481.5 5,772.8
Prepaid expenses 7,137.6 5,540.8
Other current assets 142.2 149.5
Total current assets 30,204.3 25,727.0
Investments (Note 7) 2,877.6 3,052.2
Goodwill 5,768.2 4,939.7
Other intangibles, net 6,636.1 6,906.6
Deferred tax assets 6,655.3 5,477.3
Property and equipment, net of accumulated depreciation of $11,427.8 (2024) and $11,099.3 (2023) 14,829.4 12,913.6
Other noncurrent assets 4,903.9 4,989.9
Total assets 71,874.8 64,006.3
Current Liabilities    
Short-term borrowings and current maturities of long-term debt 5,161.6 6,904.5
Accounts payable 2,924.8 2,598.8
Employee compensation 1,168.3 1,650.4
Sales rebates and discounts 12,446.8 11,689.0
Dividends payable 1,170.5 1,169.2
Other current liabilities 4,249.2 3,281.3
Total current liabilities 27,121.2 27,293.2
Noncurrent Liabilities    
Long-term debt 23,730.4 18,320.8
Accrued retirement benefits (Note 9) 1,420.4 1,438.8
Long-term income taxes payable 3,496.6 3,849.2
Other noncurrent liabilities 2,470.7 2,240.6
Total noncurrent liabilities 31,118.1 25,849.4
Commitments and Contingencies (Note 10)
Eli Lilly and Company Shareholders' Equity    
Common stock 594.2 593.6
Additional paid-in capital 7,214.2 7,250.4
Retained earnings 13,178.0 10,312.3
Employee benefit trust (3,013.2) (3,013.2)
Accumulated other comprehensive loss (Note 11) (4,378.5) (4,327.0)
Cost of common stock in treasury (32.7) (44.2)
Total Eli Lilly and Company shareholders' equity 13,562.0 10,771.9
Noncontrolling interests 73.5 91.8
Total equity 13,635.5 10,863.7
Total liabilities and equity $ 71,874.8 $ 64,006.3